MEDICINOVA INC

MNOV · Nasdaq · SIC 2834: Pharmaceutical Preparations
423
SEC Filings

Business Summary

MediciNova, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious diseases with unmet medical needs, targeting the U.S. market. Its primary product candidates are MN-166 (ibudilast) for neurological disorders including progressive multiple sclerosis, ALS, chemotherapy-induced peripheral neuropathy, and glioblastoma, and MN-001 (tipelukast) for fibrotic and metabolic disorders including NAFLD and hypertriglyceridemia. The company has no approved products and relies on clinical-stage development.

Next Earnings

Q2 FY2026 — expected 2026-07-15

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionMNOVdiscussed_in_filing Healthcare & Bio
topic_mentionMNOVdiscussed_in_filing Healthcare & Bio
topic_mentionMNOVdiscussed_in_filing Healthcare & Bio
topic_mentionMNOVdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-102025-12-310001193125-26-100432EDGAR57K words
2025-02-192024-12-310000950170-25-023301EDGAR—
2024-02-152023-12-310000950170-24-015920EDGAR—
2023-02-162022-12-310000950170-23-003054EDGAR—
2022-02-162021-12-310001564590-22-005388EDGAR—
2021-02-192020-12-310001564590-21-006771EDGAR—
2020-02-132019-12-310001564590-20-004605EDGAR—
2019-02-132018-12-310001564590-19-002835EDGAR—
2018-02-132017-12-310001564590-18-001957EDGAR—
2017-02-142016-12-310001564590-17-001547EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-122025-09-300001193125-25-277779EDGAR15K words
2025-08-142025-06-300000950170-25-109041EDGAR—
2025-05-132025-03-310000950170-25-070461EDGAR—
2024-11-132024-09-300000950170-24-126343EDGAR—
2024-08-082024-06-300000950170-24-094092EDGAR—
2024-05-092024-03-310000950170-24-056996EDGAR—
2023-11-092023-09-300000950170-23-062079EDGAR—
2023-08-092023-06-300000950170-23-040621EDGAR—
2023-05-112023-03-310000950170-23-021279EDGAR—
2022-11-102022-09-300001564590-22-037391EDGAR—
2022-08-112022-06-300001564590-22-029126EDGAR—
2022-05-122022-03-310001564590-22-019872EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-200001193125-26-060232EDGAR13K words
2025-12-300001193125-25-335917EDGAR—
2025-08-010001193125-25-170744EDGAR—
2025-06-180000950170-25-087924EDGAR—
2025-03-110001193125-25-051990EDGAR—
2024-06-120000950170-24-072461EDGAR—
2024-04-010001193125-24-083356EDGAR—
2023-08-070001193125-23-204956EDGAR—
2023-06-220001193125-23-172585EDGAR—
2023-06-140000950170-23-027823EDGAR—

423 total filings indexed. 391 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

progressive-multiple-sclerosis amyotrophic-lateral-sclerosis nonalcoholic-fatty-liver-disease-(nafld) hypertriglyceridemia chemotherapy-induced-peripheral-neuropathy degenerative-cervical-myelopathy glioblastoma acute-respiratory-distress-syndrome-(ards)

Company Identity

CIK0001226616
TickerMNOV
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 9c6dd65ce1a6760f5660f2f787d54491eb4dfc8ecb0e8017213713ee811642c0
parent: eeb091ea25417a54536ce367607a708f9fba82e19f53b8450784ea1e71150810
content hash: e753dd6972c1bb00ea5b52ced59c7ea6174dba14193a87f506bd7496af78b789
signed: 2026-04-13T04:46:18.705Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf